查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1874402

視神經脊髓炎治療：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Neuromyelitis Optica Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球視神經脊髓炎治療藥物市場規模估計為 4,980 萬美元，預計到 2031 年將擴大到 6,110 萬美元，2025 年至 2031 年的複合年成長率為 3.0%。

視神經脊髓炎 (NMO) 是一種罕見的中樞神經系統 (CNS) 疾病症候群，主要涉及視神經和脊髓。 NMO 患者會出現視神經炎，導致眼睛疼痛和視力喪失。橫貫性脊髓炎也可能發生，導致四肢肌肉無力、麻木，有時甚至癱瘓，同時伴隨感覺障礙以及膀胱和腸道功能障礙。 NMO 會導致髓鞘（一種包裹神經纖維並幫助細胞間傳遞神經訊號的脂肪物質）的流失。這種症候群會損傷神經纖維，並留下壞死組織區域。在 NMO 中，由於一些尚未明確的原因，免疫系統細胞和抗體會攻擊並破壞視神經和脊髓中的髓鞘細胞。視神經脊髓炎藥物是用於治療該疾病的藥物；在本報告中，我們重點介紹了糖皮質素（如Methylprednisolone）和免疫球蛋白（如靜脈注射免疫球蛋白 (IVIG)）。

視神經脊髓炎 (NMO) 治療市場的主要推動力是這種罕見自體免疫疾病（也稱為視神經脊髓炎頻譜障礙 (NMOSD)）盛行率的上升和診斷準確性的提高。除了醫療專業人員對疾病的認知不斷提高外，AQP4-IgG 抗體檢測等診斷技術的進步也使得 NMO 的診斷更加早期和準確，從而增加了符合治療條件的患者人數。此外，近期核准的標靶治療，如Eculizumab、伊內利珠單抗和沙曲珠單抗，徹底改變了治療格局，與傳統免疫抑制劑相比，提供了更有效、特異性的治療方法。這些突破不僅改善了患者的預後，也刺激了對 NMO 治療研發的投資和創新。製藥公司對罕見疾病的日益關注，以及孤兒藥認定和快速核准等有利的監管獎勵，進一步推動了市場成長。此外，醫療保健支出（尤其是在已開發地區）的成長以及患者權益倡導工作的加強，也有助於提高患者獲得治療的機會，並提高人們對這種曾經被忽視的疾病的認知。

儘管取得了令人鼓舞的進展，NMO治療市場仍面臨許多挑戰，可能阻礙其長期成長。首先，新核准生物製藥的高昂價格構成了一大障礙，尤其是在健保體系薄弱或缺失的中低收入國家，病患難以取得這些藥物。例如，Eculizumab等藥物的定價每年可達數十萬美元，給醫療系統和患者都帶來了沉重的負擔，並可能阻礙其廣泛應用。此外，NMO是一種罕見且複雜的疾病，難以招募到足夠的受試者進行大規模臨床試驗，減緩了藥物研發和創新的步伐。此疾病的表現型變異性以及與多發性硬化症的症狀重疊也帶來了診斷挑戰，可能導致誤診和不當治療。此外，新型治療方法的長期安全性數據仍然有限，這可能會使臨床醫生和監管機構在更廣泛地採用這些治療方法時感到擔憂。最後，該市場仍然高度專業化，製藥公司數量有限，限制了競爭，並造成了供應鏈的脆弱性。如果 NMO 治療領域的最新進展要轉化為各種醫療保健環境中患者療效的改善，那麼應對這些挑戰至關重要。

本報告旨在依地區/國家、類型和應用對全球視神經脊髓炎治療市場進行全面分析，重點關注總銷售額、市場佔有率和主要企業的排名。

本報告中關於脊髓炎治療藥物市場規模、估算和預測的數據均以收益為準，以2024年為基準年，並涵蓋2020年至2031年的歷史數據和預測數據。報告的定量和定性分析將幫助讀者制定脊髓炎治療藥物的業務和成長策略，評估市場競爭，分析公司在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

依類型分類的區隔市場

  • 糖皮質素
  • 免疫療法
  • 其他

應用領域

  • 急性發作
  • 緩解期預防性治療

依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Neuromyelitis Optica Drug was estimated to be worth US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 61.1 million by 2031 with a CAGR of 3.0% during the forecast period 2025-2031.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.

Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.

This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Neuromyelitis Optica Drug by region & country, by Type, and by Application.

The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.

Market Segmentation

By Company

  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

Segment by Type

  • Glucocorticoids
  • Immunotherapies
  • Others

Segment by Application

  • Acute Attack
  • Remission Prophylactic Treatment

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Neuromyelitis Optica Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Neuromyelitis Optica Drug in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Neuromyelitis Optica Drug Product Introduction
  • 1.2 Global Neuromyelitis Optica Drug Market Size Forecast (2020-2031)
  • 1.3 Neuromyelitis Optica Drug Market Trends & Drivers
    • 1.3.1 Neuromyelitis Optica Drug Industry Trends
    • 1.3.2 Neuromyelitis Optica Drug Market Drivers & Opportunity
    • 1.3.3 Neuromyelitis Optica Drug Market Challenges
    • 1.3.4 Neuromyelitis Optica Drug Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Neuromyelitis Optica Drug Players Revenue Ranking (2024)
  • 2.2 Global Neuromyelitis Optica Drug Revenue by Company (2020-2025)
  • 2.3 Key Companies Neuromyelitis Optica Drug Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Neuromyelitis Optica Drug Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Neuromyelitis Optica Drug
  • 2.6 Neuromyelitis Optica Drug Market Competitive Analysis
    • 2.6.1 Neuromyelitis Optica Drug Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Neuromyelitis Optica Drug Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Glucocorticoids
    • 3.1.2 Immunotherapies
    • 3.1.3 Others
  • 3.2 Global Neuromyelitis Optica Drug Sales Value by Type
    • 3.2.1 Global Neuromyelitis Optica Drug Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Neuromyelitis Optica Drug Sales Value, by Type (2020-2031)
    • 3.2.3 Global Neuromyelitis Optica Drug Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Acute Attack
    • 4.1.2 Remission Prophylactic Treatment
  • 4.2 Global Neuromyelitis Optica Drug Sales Value by Application
    • 4.2.1 Global Neuromyelitis Optica Drug Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Neuromyelitis Optica Drug Sales Value, by Application (2020-2031)
    • 4.2.3 Global Neuromyelitis Optica Drug Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Neuromyelitis Optica Drug Sales Value by Region
    • 5.1.1 Global Neuromyelitis Optica Drug Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025)
    • 5.1.3 Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031)
    • 5.1.4 Global Neuromyelitis Optica Drug Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.2.2 North America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.3.2 Europe Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Neuromyelitis Optica Drug Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.5.2 South America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Neuromyelitis Optica Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Neuromyelitis Optica Drug Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.3.2 United States Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.4.2 Europe Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.5.2 China Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.6.2 Japan Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.7.2 South Korea Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.9.2 India Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Pfizer
    • 7.1.1 Pfizer Profile
    • 7.1.2 Pfizer Main Business
    • 7.1.3 Pfizer Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.1.4 Pfizer Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Pfizer Recent Developments
  • 7.2 Fresenius
    • 7.2.1 Fresenius Profile
    • 7.2.2 Fresenius Main Business
    • 7.2.3 Fresenius Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.2.4 Fresenius Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Fresenius Recent Developments
  • 7.3 Teva
    • 7.3.1 Teva Profile
    • 7.3.2 Teva Main Business
    • 7.3.3 Teva Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.3.4 Teva Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Teva Recent Developments
  • 7.4 Sandoz
    • 7.4.1 Sandoz Profile
    • 7.4.2 Sandoz Main Business
    • 7.4.3 Sandoz Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.4.4 Sandoz Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Sandoz Recent Developments
  • 7.5 Intas
    • 7.5.1 Intas Profile
    • 7.5.2 Intas Main Business
    • 7.5.3 Intas Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.5.4 Intas Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Intas Recent Developments
  • 7.6 Gyjtrs
    • 7.6.1 Gyjtrs Profile
    • 7.6.2 Gyjtrs Main Business
    • 7.6.3 Gyjtrs Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Gyjtrs Recent Developments
  • 7.7 NANG KUANG
    • 7.7.1 NANG KUANG Profile
    • 7.7.2 NANG KUANG Main Business
    • 7.7.3 NANG KUANG Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.7.5 NANG KUANG Recent Developments
  • 7.8 Tianjin Kingyork
    • 7.8.1 Tianjin Kingyork Profile
    • 7.8.2 Tianjin Kingyork Main Business
    • 7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Tianjin Kingyork Recent Developments
  • 7.9 Baxter
    • 7.9.1 Baxter Profile
    • 7.9.2 Baxter Main Business
    • 7.9.3 Baxter Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.9.4 Baxter Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Baxter Recent Developments
  • 7.10 CSL
    • 7.10.1 CSL Profile
    • 7.10.2 CSL Main Business
    • 7.10.3 CSL Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.10.4 CSL Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.10.5 CSL Recent Developments
  • 7.11 Grifols
    • 7.11.1 Grifols Profile
    • 7.11.2 Grifols Main Business
    • 7.11.3 Grifols Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.11.4 Grifols Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Grifols Recent Developments
  • 7.12 Octapharma
    • 7.12.1 Octapharma Profile
    • 7.12.2 Octapharma Main Business
    • 7.12.3 Octapharma Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.12.4 Octapharma Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Octapharma Recent Developments
  • 7.13 CBOP
    • 7.13.1 CBOP Profile
    • 7.13.2 CBOP Main Business
    • 7.13.3 CBOP Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.13.4 CBOP Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.13.5 CBOP Recent Developments

8 Industry Chain Analysis

  • 8.1 Neuromyelitis Optica Drug Industrial Chain
  • 8.2 Neuromyelitis Optica Drug Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Neuromyelitis Optica Drug Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Neuromyelitis Optica Drug Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Neuromyelitis Optica Drug Market Trends
  • Table 2. Neuromyelitis Optica Drug Market Drivers & Opportunity
  • Table 3. Neuromyelitis Optica Drug Market Challenges
  • Table 4. Neuromyelitis Optica Drug Market Restraints
  • Table 5. Global Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Neuromyelitis Optica Drug Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Neuromyelitis Optica Drug Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Neuromyelitis Optica Drug
  • Table 10. Global Neuromyelitis Optica Drug Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Neuromyelitis Optica Drug Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Neuromyelitis Optica Drug Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Neuromyelitis Optica Drug Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Neuromyelitis Optica Drug Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Neuromyelitis Optica Drug Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Neuromyelitis Optica Drug Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Neuromyelitis Optica Drug Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Neuromyelitis Optica Drug Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Neuromyelitis Optica Drug Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Neuromyelitis Optica Drug Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Neuromyelitis Optica Drug Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Neuromyelitis Optica Drug Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Neuromyelitis Optica Drug Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Neuromyelitis Optica Drug Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Pfizer Basic Information List
  • Table 32. Pfizer Description and Business Overview
  • Table 33. Pfizer Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Pfizer (2020-2025)
  • Table 35. Pfizer Recent Developments
  • Table 36. Fresenius Basic Information List
  • Table 37. Fresenius Description and Business Overview
  • Table 38. Fresenius Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Fresenius (2020-2025)
  • Table 40. Fresenius Recent Developments
  • Table 41. Teva Basic Information List
  • Table 42. Teva Description and Business Overview
  • Table 43. Teva Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Teva (2020-2025)
  • Table 45. Teva Recent Developments
  • Table 46. Sandoz Basic Information List
  • Table 47. Sandoz Description and Business Overview
  • Table 48. Sandoz Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Sandoz (2020-2025)
  • Table 50. Sandoz Recent Developments
  • Table 51. Intas Basic Information List
  • Table 52. Intas Description and Business Overview
  • Table 53. Intas Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Intas (2020-2025)
  • Table 55. Intas Recent Developments
  • Table 56. Gyjtrs Basic Information List
  • Table 57. Gyjtrs Description and Business Overview
  • Table 58. Gyjtrs Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Gyjtrs (2020-2025)
  • Table 60. Gyjtrs Recent Developments
  • Table 61. NANG KUANG Basic Information List
  • Table 62. NANG KUANG Description and Business Overview
  • Table 63. NANG KUANG Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of NANG KUANG (2020-2025)
  • Table 65. NANG KUANG Recent Developments
  • Table 66. Tianjin Kingyork Basic Information List
  • Table 67. Tianjin Kingyork Description and Business Overview
  • Table 68. Tianjin Kingyork Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Tianjin Kingyork (2020-2025)
  • Table 70. Tianjin Kingyork Recent Developments
  • Table 71. Baxter Basic Information List
  • Table 72. Baxter Description and Business Overview
  • Table 73. Baxter Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Baxter (2020-2025)
  • Table 75. Baxter Recent Developments
  • Table 76. CSL Basic Information List
  • Table 77. CSL Description and Business Overview
  • Table 78. CSL Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of CSL (2020-2025)
  • Table 80. CSL Recent Developments
  • Table 81. Grifols Basic Information List
  • Table 82. Grifols Description and Business Overview
  • Table 83. Grifols Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Grifols (2020-2025)
  • Table 85. Grifols Recent Developments
  • Table 86. Octapharma Basic Information List
  • Table 87. Octapharma Description and Business Overview
  • Table 88. Octapharma Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Octapharma (2020-2025)
  • Table 90. Octapharma Recent Developments
  • Table 91. CBOP Basic Information List
  • Table 92. CBOP Description and Business Overview
  • Table 93. CBOP Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of CBOP (2020-2025)
  • Table 95. CBOP Recent Developments
  • Table 96. Key Raw Materials Lists
  • Table 97. Raw Materials Key Suppliers Lists
  • Table 98. Neuromyelitis Optica Drug Downstream Customers
  • Table 99. Neuromyelitis Optica Drug Distributors List
  • Table 100. Research Programs/Design for This Report
  • Table 101. Key Data Information from Secondary Sources
  • Table 102. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Neuromyelitis Optica Drug Product Picture
  • Figure 2. Global Neuromyelitis Optica Drug Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Neuromyelitis Optica Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Neuromyelitis Optica Drug Report Years Considered
  • Figure 5. Global Neuromyelitis Optica Drug Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Neuromyelitis Optica Drug Revenue in 2024
  • Figure 7. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Glucocorticoids Picture
  • Figure 9. Immunotherapies Picture
  • Figure 10. Others Picture
  • Figure 11. Global Neuromyelitis Optica Drug Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Neuromyelitis Optica Drug Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Acute Attack
  • Figure 14. Product Picture of Remission Prophylactic Treatment
  • Figure 15. Global Neuromyelitis Optica Drug Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global Neuromyelitis Optica Drug Sales Value Market Share by Application, 2024 & 2031
  • Figure 17. North America Neuromyelitis Optica Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 18. North America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 19. Europe Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 20. Europe Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Asia Pacific Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Asia Pacific Neuromyelitis Optica Drug Sales Value by Region (%), 2024 VS 2031
  • Figure 23. South America Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. South America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 25. Middle East & Africa Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. Middle East & Africa Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Key Countries/Regions Neuromyelitis Optica Drug Sales Value (%), (2020-2031)
  • Figure 28. United States Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. United States Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 30. United States Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 31. Europe Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Europe Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 33. Europe Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 34. China Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. China Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 36. China Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 37. Japan Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. Japan Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 39. Japan Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 40. South Korea Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. South Korea Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 42. South Korea Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Southeast Asia Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Southeast Asia Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Southeast Asia Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 46. India Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. India Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 48. India Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 49. Neuromyelitis Optica Drug Industrial Chain
  • Figure 50. Neuromyelitis Optica Drug Manufacturing Cost Structure
  • Figure 51. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 52. Bottom-up and Top-down Approaches for This Report
  • Figure 53. Data Triangulation
  • Figure 54. Key Executives Interviewed